Costimulatory BiTEs targeting a variety of solid tumors are currently evaluated in phase I/II trials: MUC16, PSMA, EGFR, PD-L1, HER2, Nectin-4, and FAP (targeting tumor-associated fibroblasts) (Table 5). Here, EGFR is linked to neoplasm.